Vera Therapeutics to Join Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company in the advanced stages of clinical development, is dedicated to creating and commercializing innovative treatments for severe immunological diseases. This June, the company's management team will be actively involved in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 10-13, 2024, at the Loews Miami Beach Hotel in Miami Beach, Florida. Notably, Vera's Chief Executive Officer, Marshall Fordyce, M.D., is set to deliver a presentation on June 12 at 10:40 AM EDT. Beyond the presentation, Vera's team will also engage in one-on-one meetings with investors.

Vera Therapeutics is committed to advancing medical treatments that address the underlying causes of immunological diseases, with the aim of transforming patient care. The company's primary focus is on its lead product candidate, atacicept. This fusion protein is administered subcutaneously once a week and works by blocking B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). Both BAFF and APRIL are instrumental in stimulating B cells and plasma cells to produce autoantibodies, which play a significant role in autoimmune diseases such as IgA nephropathy (IgAN, also known as Berger’s disease) and lupus nephritis.

Vera is also exploring the potential application of atacicept in other diseases where reducing autoantibodies could be beneficial. Additionally, the company is developing MAU868, a monoclonal antibody designed to neutralize the BK virus (BKV). BKV is a polyomavirus that can lead to serious complications, particularly in kidney transplant patients. Vera Therapeutics maintains full global developmental and commercial rights to both atacicept and MAU868.

Vera's mission is to revolutionize the treatment landscape for patients suffering from severe immunological conditions. By targeting the root causes of these diseases, Vera aims to set new standards in patient care, offering hope and improved outcomes for those affected. The company's involvement in significant industry conferences like the Goldman Sachs Annual Global Healthcare Conference underscores its commitment to innovation and collaboration within the biotechnological and medical communities.

The conference will provide Vera Therapeutics with a platform to showcase its cutting-edge research and development efforts, as well as to engage with potential investors and partners. Through such interactions, Vera hopes to further its mission of bringing transformative treatments to market, ultimately benefiting patients worldwide.

In summary, Vera Therapeutics is a pioneering biotechnology company focused on developing advanced treatments for severe immunological diseases. With a strong emphasis on their lead product candidate, atacicept, and the promising MAU868, Vera is at the forefront of medical innovation. The company's participation in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference highlights its dedication to advancing healthcare solutions and engaging with the broader medical and investment communities.